{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T02:47:49Z","timestamp":1764211669275},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1406,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p>Clopidogrel is important for the management of acute coronary syndromes and, along with aspirin, is recommended in the American College of Cardiology\/American Heart Association guideline. It is also used along with aspirin, during the placement of coronary artery stents. Clopidogrel resistance was recognized in such procedures, as several patients did not have the anticipated platelet aggregation response to an ex vivo adenosine diphosphate challenge. From the EXCELSIOR study, which investigated the phenomenon, it was appreciated that it was present prior to treatment with clopidogrel and was therefore an intrinsic property of the patient's platelets. From other studies, it was appreciated that the patients who had clopidogrel resistance had a defective allele *2\/ in the CYP2C19 gene. Furthermore, there was a dose response evident in that the homozygotes CYP2C19*2\/*2 had platelets that responded even less well to clopidogrel than the heterozygotes CYP2C19*2 that responded less well than the wild\u2010type homozygote. The involvement of the phenomenon with CYP2C19 led some to believe that it was a pharmacokinetic issue. However, the major oxidative metabolic pathway for clopidogrel by which the reactive intermediate is formed is CYP3A4. It is suggested that there is a linkage between a polymorphism of the platelet receptor P2Y12 and the polymorphism of CYP2C19.<\/jats:p>","DOI":"10.1177\/0091270009332433","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T03:00:21Z","timestamp":1235703621000},"page":"506-512","source":"Crossref","is-referenced-by-count":35,"title":["Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?"],"prefix":"10.1002","volume":"49","author":[{"given":"Neville F.","family":"Ford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000037106.76139.53"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613462"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi684"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200610000-00011"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.034"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614133"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.11.1288"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.11.3.663"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3027"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510446103"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-02-0105"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100139"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000112378.09325.F9"},{"issue":"2","key":"e_1_2_7_18_2","first-page":"99","article-title":"In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation","volume":"37","author":"Kurihara A","year":"2005","journal-title":"Drug Metab Rev"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.1.53"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000047060.60595.CC"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160869.75810.98"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.536276"},{"key":"e_1_2_7_23_2","unstructured":"P450 table.http:www.medicine.iupui.eduFlockharttable.htm."},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000088780.57432.43"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060664"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0471-0"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-013052"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02162.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614344"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.090"},{"key":"e_1_2_7_32_2","article-title":"Antiplatelet action of clopidogrel is not influenced by proton pump inhibitors in patients with coronary artery disease under clopidogrel maintainence treatment","volume":"29","author":"Sibbing D","year":"2008","journal-title":"Eur Heart J"},{"key":"e_1_2_7_33_2","article-title":"The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting","volume":"29","author":"Zairis M","year":"2008","journal-title":"Eur Heart J"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.065"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.08.009"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.25.3051"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.07.007"},{"key":"e_1_2_7_38_2","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","article-title":"Absorption, metabolization and antiplatelet effects of 30\u2010, 600\u2010, and 900m\u2010mg loading doses of clopidogrel; results of the ISAR\u2010CHOICE (intracoronary stenting and antithrombotic regimen: choose between three high oral doses for immediate clopidogrel effect) trial","volume":"112","author":"Beckerath N","year":"2005","journal-title":"Circulation"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f1b2be"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.11.065"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm545"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.056"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.01.051"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-8-59"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2007.01.012"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000085073.69189.88"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009332433","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009332433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:35:08Z","timestamp":1697150108000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009332433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1177\/0091270009332433"],"URL":"https:\/\/doi.org\/10.1177\/0091270009332433","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}